Clinical trial
Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally…
NCT00063947 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00063947 |
|---|---|
| Title | Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer |
| Official title | A Phase I Study of OSI-774 in Combination With Gemcitabine and Radiation in Locally Advanced, Non-Operable Pancreatic Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer |
| Intervention type | Drug, Other, Radiation |
| Interventions | erlotinib hydrochloride, gemcitabine hydrochloride, radiation therapy, laboratory biomarker analysis |
| Enrollment | 28 |
| Start date | May 1, 2003 |
| Primary completion | Feb 1, 2009 |
| First posted | Jul 9, 2003 |
| Last update posted | Jun 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: